Your AI-Trained Oncology Knowledge Connection!

Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma : Episode 10

Video

February 13, 2023

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

Author(s):

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

Now Viewing

EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP: 14.Targets in Multiple Myeloma: GPRC5D

EP: 15.Targets in Multiple Myeloma: FcRH5

EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment

EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity

Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity

Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity

Latest Conference Coverage

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

Dr Scilipoti on the Value of Life Expectancy Assessments to Guide Prostate Cancer Treatment Strategies

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma

EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment

EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma

EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical

EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma

EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse

EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma

EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma

EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection

EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM

EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma

EP: 14.Targets in Multiple Myeloma: GPRC5D

EP: 15.Targets in Multiple Myeloma: FcRH5

EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma

EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment

EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?

EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care

Newsletter

Latest CME

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Addressing Unmet Needs in HER2+ Metastatic BTC

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Addressing Unmet Needs in HER2+ Metastatic BTC

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Latest Conference Coverage